CLINICAL PROTEOMICS TECHNOLOGY ASSESSMENT FOR CANCER

癌症临床蛋白质组学技术评估

• 批准号: 8361581
• 负责人: Thomas A Neubert
• 金额: $ 0.13万
• 依托单位: ROCKEFELLER UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361581
• 关键词: Asses; Biological Markers; Clinical; Funding; Goals; Grant; Malignant Neoplasms; Metric; National Center for Research Resources; Phase; Principal Investigator; Proteomics; Reproducibility; Research; Research Infrastructure; Resources; Sampling; Source; Technology; Technology Assessment; United States National Institutes of Health; cost; macromolecule; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The goal of this program is to asses if proteomics technology is sufficiently robust and reproducible to be useful for biomarker discovery and verification. In the first phase of the project the focus was to develop metrics and SOP's to assess and maximize inter-lab reproducibility. In the second phase, a large number of clinical samples will be analyzed to discover and verify cancer biomarkers.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 该计划的目标是评估蛋白质组学技术是否足够强大和可重复性，以用于生物标记物的发现和验证。在项目的第一阶段，重点是制定衡量标准和标准操作规程，以评估和最大限度地提高实验室间的重复性。在第二阶段，将对大量临床样本进行分析，以发现和验证癌症生物标志物。